Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-SOUND: Abbreviated vs Conventional Dabigatran in AF Cardioversion
NCT03975062Phase 4Unknown
- Sponsor
- Ural State Medical University
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Ural State Medical University. Primary endpoint: Proportion of patients with new magnetic resonance imaging (MRI) detected cerebral embolic events. Status: unknown.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03975062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975062.